T cells, also known as T lymphocytes, are a type of white blood cell that play a crucial role in the body’s immune response. They help to identify and eliminate harmful cells, such as cancer cells, from the body. In recent years, there has been a growing interest in using engineered T cells as a means of treating cancer.

Engineered T cells are T cells that have been genetically modified in the laboratory to enhance their ability to recognize and attack cancer cells. This is achieved by introducing new genes into the T cells that code for specific proteins, called chimeric antigen receptors (CARs), which allow the T cells to target specific types of cancer cells.

One of the advantages of using engineered T cells to treat cancer is that they are a form of immunotherapy, which means they work by harnessing the power of the body’s own immune system to fight cancer. This makes them a more personalized and effective form of treatment, as the T cells are specifically tailored to each patient’s unique cancer cells.

There are several different approaches to engineering T cells, and each approach has its own set of benefits and drawbacks. For example, some researchers are working on developing T cells that are equipped with CARs that can target a specific protein found on cancer cells, while others are developing T cells that are equipped with CARs that target specific cell surface markers on cancer cells.

According to the report published by Allied Market Research, the Global Engineered T Cells Market Size generated USD 9,668.0 million in 2020 and is estimated to reach USD 149,650.6 million by 2030, witnessing a 32.5% from 2021 to 2030

Top T Cell Engineering Companies

• Amgen Inc
• AthenexInc
• Bellicum Pharmaceuticals, Inc.
• Bristol-Myers Squibb
• Eli Lilly And Company
• Gilead Sciences, Inc.
• Novartis AG
• Oxford BiomedicaPlc
• Pfizer Inc.
• Precision Biosciences Inc.

Get Sample PDF Report with Graphs and Figures Here

What is the advantage of engineered TCR T cells over CAR T cells?

Engineered TCR T cells and CAR T cells are two types of chimeric antigen receptor (CAR) T cell therapies that are being developed for the treatment of cancer.

The main advantage of engineered TCR T cells over CAR T cells is that TCRs can recognize and bind to peptides presented by the major histocompatibility complex (MHC) molecules on the surface of cancer cells, while CARs can only bind to antigens expressed on the cell surface. This allows TCR T cells to potentially target a wider range of cancer types, including cancers that do not express the antigens targeted by CAR T cells. Additionally, TCR T cells have a more natural and evolved mechanism of recognizing cancer cells compared to CAR T cells.

What are the Factors that Drive the Engineered T Cells Market?

The following factors are driving the growth of the engineered T cells market:

• Increasing prevalence of cancer and other chronic diseases
• Growing demand for personalized medicine
• Advancements in cell engineering technology
• Increasing investment and funding for research and development in the field of cell therapy
• Rising number of clinical trials for engineered T cell therapies
• Growing demand for immunotherapies for cancer treatment
• Strong pipeline of engineered T-cell therapies in various stages of development
• Favorable regulatory landscape for cell therapy products
• Increasing collaborations between academic institutes, biotechnology and pharmaceutical companies to develop new cell therapies
• Growing awareness and adoption of cell therapies in developed and developing countries.

 

Contact:  

David Correa
USA/Canada (Toll-Free): +1-800-792-5285, +1-503-894-6022
Fax: +1(855)550-5975
help@alliedmarketresearch.com